Production of canine soluble CD40 ligand to induce maturation of monocyte derived dendritic cells for cancer immunotherapy

Veterinary Immunology and Immunopathology

Volumn 156, Issue 1-2, 2013, Pages 121-127

  Wijewardana, Viskam ^a   Sugiura, Kikuya ^a   Yahata, Mana ^a   Akazawa, Takashi ^b   Wijesekera, Daluthgamage Patsy H ^a   Imamoto, Shigeki ^a   Hatoya, Shingo ^a   Inoue, Norimitsu ^b   Inaba, Toshio ^a  

^a Osaka Prefecture University   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Dendritic cells; Expression vector; Maturation; Soluble CD40 ligand

Indexed keywords

CD40 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; SIGNAL PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL MATURATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EXPRESSION VECTOR; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION;

DENDRITIC CELLS; EXPRESSION VECTOR; MATURATION; SOLUBLE CD40 LIGAND;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CD40 LIGAND; DENDRITIC CELLS; DOGS; IMMUNOTHERAPY; INTERLEUKIN-12 SUBUNIT P40; MOLECULAR SEQUENCE DATA; MONOCYTES; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 84887063082     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.09.016     Document Type: Article

References (24)

1. Armitage R.J., Fanslow W.C., Strockbine L., Sato T.A., Clifford K.N., Macduff B.M., Anderson D.M., Gimpel S.D., Davis-Smith T., Maliszewski C.R. Molecular and biological characterization of a murine ligand for CD40. Nature 1992, 357:80-82.
2. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
3. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
4. Chow A., Toomre D., Garrett W., Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 2002, 418:988-994.
5. Fecteau J.F., Néron S. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J. Immunol. 2003, 171:4621-4629.
6. Kato K., Takaue Y., Wakasugi H. T-cell-conditioned medium efficiently induces the maturation and function of human dendritic cells. J. Leukoc. Biol. 2001, 70:941-949.
7. Kiefer F., Arnold K., Künzli M., Bordoli L., Schwede T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009, 37:D387-D392.
8. Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.-A., Maliszewski C., Shortman K., Cebon J., Maraskovsky E. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002, 100:1362-1372.
9. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002, 23:445-4459.
10. Mackey M.F., Gunn J.R., Maliszewsky C., Kikutani H., Noelle R.J., Barth R.J. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 1998, 161:2094-2498.
11. Mazzei G.J., Edgerton M.D., Losberger C., Lecoanet-Henchoz S., Graber P., Durandy A., Gauchat J.F., Bernard A., Allet B., Bonnefoy J.Y. Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem. 1995, 270:7025-7028.
12. Mito K., Sugiura K., Ueda K., Hori T., Akazawa T., Yamate J., Nakagawa H., Hatoya S., Inaba M., Inoue N., Ikehara S., Inaba T. IFNγ markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Res. 2010, 70:7093-7101.
13. Nelson E.L., Strobl S., Subleski J., Prieto D., Kopp W.C., Nelson P.J. Cycling of human dendritic cell effector phenotypes in response to TNF-α: modification of the current "maturation" paradigm and implications for in vivo immunoregulation. FASEB J. 1999, 13:2021-2030.
14. Palucka K., Ueno H., Fay J., Banchereau J. Dendritic cells and immunity against cancer. J. Intern. Med. 2011, 269:64-73.
15. Sorenmo K.U., Krick E., Coughlin C.M., Overley B., Gregor T.P., Vonderheide R.H., Mason N.J. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS ONE 2011, 6:e24167.
16. Steinman R.M., Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001, 94:459-473.
17. Sugiura K., Akazawa T., Fujimoto M., Wijewardana V., Mito K., Hatoya S., Taketani S., Komori M., Inoue N., Inaba T. Construction of an expression vector for improved secretion of canine IL-18. Vet. Immunol. Immunopathol. 2008, 126:388-391.
18. Sugiura K., Wijewardana V., Fujimoto M., Akazawa T., Yahata M., Mito K., Hatoya S., Inoue N., Inaba T. Effect of IL-12 on canine dendritic cell maturation following differentiation induced by granulocyte-macrophage CSF and IL-4. Vet. Immunol. Immunopathol. 2010, 137:322-326.
19. Sun Y., Peng D., Lecanda J., Schmitz V., Barajas M., Qian C., Prieto J. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther. 2000, 7:1467-1476.
20. Von Euler H., Sadeghi A., Carlsson B., Rivera P., Loskog A., Segall T., Korsgren O., Tötterman T.H. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J. Immunother. 2008, 31:377-384.
21. Wang Y.-S., Chi K.-H., Chu R.-M. Cytokine profiles of canine monocyte-derived dendritic cells as a function of lipopolysaccharide- or tumor necrosis factor-alpha-induced maturation. Vet. Immunol. Immunopathol. 2007, 118:186-198.
22. Wijewardana V., Sugiura K., Oichi T., Fujimoto M., Akazawa T., Hatoya S., Inaba M., Ikehara S., Jayaweera T.S.P., Inaba T. Generation of canine dendritic cells from peripheral blood monocytes without using purified cytokines. Vet. Immunol. Immunopathol 2006, 114:37-48.
23. Würtzen P.A., Nissen M.H., Claesson M.H. Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand. J. Immunol. 2001, 53:579-587.
24. Zhou L.J., Tedder T.F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2588-2592.